Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC
mi
from
Tampa, FL
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC
mi
from
Tampa, FL
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Oncology Specialists, SC Lutheran General Advanced Care
mi
from
Park Ridge, IL
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Oncology Specialists, SC Lutheran General Advanced Care
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Indiana University Health Goshen Center for Cancer SC
mi
from
Goshen, IN
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Indiana University Health Goshen Center for Cancer SC
mi
from
Goshen, IN
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Floyd Memorial Cancer Center of Indiana Floyd Memorial
mi
from
New Albany, IN
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Floyd Memorial Cancer Center of Indiana Floyd Memorial
mi
from
New Albany, IN
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Washington University School of Medicine Regulatory
mi
from
St. Louis, MO
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Washington University School of Medicine Regulatory
mi
from
St. Louis, MO
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Nebraska Methodist Hospital Estabrook Cancer Center
mi
from
Omaha, NE
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Nebraska Methodist Hospital Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Saint Barnabas Medical Center CancerCenter of Saint Barnabas
mi
from
Livingston, NJ
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Saint Barnabas Medical Center CancerCenter of Saint Barnabas
mi
from
Livingston, NJ
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
University of New Mexico Hospital Cancer Care Alliance
mi
from
Albuquerque, NM
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
University of New Mexico Hospital Cancer Care Alliance
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
ProHealth Care
mi
from
Lake Success, NY
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
ProHealth Care
mi
from
Lake Success, NY
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
mi
from
Troy, NY
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
mi
from
Troy, NY
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Duke University Medical Center Duke SC
mi
from
Durham, NC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Duke University Medical Center Duke SC
mi
from
Durham, NC
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Raleigh Hematology Oncology Clinic
mi
from
Raleigh, NC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Raleigh Hematology Oncology Clinic
mi
from
Raleigh, NC
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Cancer Centers of the Carolinas Dept. of CC of the Carolinas
mi
from
Greenville, SC
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Cancer Centers of the Carolinas Dept. of CC of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
US Oncology Central Monitoring
mi
from
Dallas, TX
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
US Oncology Central Monitoring
mi
from
Dallas, TX
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Institute of Oncology Hematology
mi
from
Laredo, TX
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Institute of Oncology Hematology
mi
from
Laredo, TX
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Virginia Cancer Specialists, PC Dept.ofFairfax SC
mi
from
Fairfax, VA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Virginia Cancer Specialists, PC Dept.ofFairfax SC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care
mi
from
Roanoke, VA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care
mi
from
Roanoke, VA
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Medical Oncology Associates PS
mi
from
Spokane, WA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Medical Oncology Associates PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated:  11/5/2014
Wenatchee Valley Medical Center Wenatchee Valley
mi
from
Wenatchee, WA
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status: Enrolling
Updated: 11/5/2014
Wenatchee Valley Medical Center Wenatchee Valley
mi
from
Wenatchee, WA
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Compassionate Cancer Center
mi
from
Corona, CA
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Compassionate Cancer Center
mi
from
Corona, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Compassionate Cancer Centre Medical Group
mi
from
Fountain Valley, CA
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Compassionate Cancer Centre Medical Group
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Facey Medical Group
mi
from
Mission Hills, CA
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Facey Medical Group
mi
from
Mission Hills, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Charleston Hematology Oncology, PA
mi
from
Charleston, SC
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Charleston Hematology Oncology, PA
mi
from
Charleston, SC
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Northern Utah Associates [Hematology/ Oncology]
mi
from
Ogden, UT
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Northern Utah Associates [Hematology/ Oncology]
mi
from
Ogden, UT
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Genesis Cancer Centre
mi
from
Hot Springs, AR
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Genesis Cancer Centre
mi
from
Hot Springs, AR
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Compassionate Cancer Care Medical Group
mi
from
Riverside, CA
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Compassionate Cancer Care Medical Group
mi
from
Riverside, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Wellmont Medical Associates-Oncology and Hematology
mi
from
Bristol, RI
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Wellmont Medical Associates-Oncology and Hematology
mi
from
Bristol, RI
Click here to add this to my saved trials
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated:  11/6/2014
Centro Oncológico Integral (COI)
mi
from
Mar del Plata,
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
Status: Enrolling
Updated: 11/6/2014
Centro Oncológico Integral (COI)
mi
from
Mar del Plata,
Click here to add this to my saved trials
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/7/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/7/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  11/17/2014
Shriners Hospitals for Children, Salt Lake City
mi
from
Salt Lake City, UT
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 11/17/2014
Shriners Hospitals for Children, Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  11/17/2014
University of Utah
mi
from
Salt Lake City, UT
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 11/17/2014
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Promoting Breast Cancer Screening in Non-adherent Women
Promoting Breast Cancer Screening in Non-adherent Women
Status: Enrolling
Updated:  11/18/2014
Reliant Medical Group
mi
from
Worcester, MA
Promoting Breast Cancer Screening in Non-adherent Women
Promoting Breast Cancer Screening in Non-adherent Women
Status: Enrolling
Updated: 11/18/2014
Reliant Medical Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Breast Cancer Survivorship & Work-Related Cognitive Limitation
The Relationship Between Biopsychosocial Functioning and Work-Related Cognitive Limitation Among Employed Breast Cancer Survivors: Case Control Study.
Status: Enrolling
Updated:  11/24/2014
Palo Alto University
mi
from
Palo Alto, CA
Breast Cancer Survivorship & Work-Related Cognitive Limitation
The Relationship Between Biopsychosocial Functioning and Work-Related Cognitive Limitation Among Employed Breast Cancer Survivors: Case Control Study.
Status: Enrolling
Updated: 11/24/2014
Palo Alto University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Genetic Evaluation of NF1 and Scoliosis Patients
Genetic Evaluation for the Scoliosis Gene(s) in Patients With Neurofibromatosis 1 and Scoliosis
Status: Enrolling
Updated:  12/1/2014
Univ of Minnesota
mi
from
Minneapolis, MN
Genetic Evaluation of NF1 and Scoliosis Patients
Genetic Evaluation for the Scoliosis Gene(s) in Patients With Neurofibromatosis 1 and Scoliosis
Status: Enrolling
Updated: 12/1/2014
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel
Status: Enrolling
Updated:  12/2/2014
M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel
Status: Enrolling
Updated: 12/2/2014
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Status: Enrolling
Updated:  12/2/2014
University of Massachusetts
mi
from
Worcester, MA
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Status: Enrolling
Updated: 12/2/2014
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Status: Enrolling
Updated:  12/2/2014
Dartmouth Hitchcock Medical Center
mi
from
Hannover, NH
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Status: Enrolling
Updated: 12/2/2014
Dartmouth Hitchcock Medical Center
mi
from
Hannover, NH
Click here to add this to my saved trials
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Status: Enrolling
Updated:  12/2/2014
Unviersity of Vermont/Fletcher Allen Health Care
mi
from
Burlington, VT
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Status: Enrolling
Updated: 12/2/2014
Unviersity of Vermont/Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Status: Enrolling
Updated:  12/3/2014
University of California, Irvine Health
mi
from
Orange, CA
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Status: Enrolling
Updated: 12/3/2014
University of California, Irvine Health
mi
from
Orange, CA
Click here to add this to my saved trials
Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
Status: Enrolling
Updated:  12/4/2014
University of Virginia
mi
from
Charlottesville, VA
Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
Status: Enrolling
Updated: 12/4/2014
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Perioperative Oral Nutrition Intervention for Patients Undergoing Radical Cystectomy
A Pilot Study of Perioperative Oral Nutrition Supplementation to Improve Nutritional Status, Post-operative Complications, Length of Stay and Readmission Rates in Patients Undergoing Radical Cystectomy
Status: Enrolling
Updated:  12/10/2014
Vanderbilt University Medical Center
mi
from
Nashville, TN
Perioperative Oral Nutrition Intervention for Patients Undergoing Radical Cystectomy
A Pilot Study of Perioperative Oral Nutrition Supplementation to Improve Nutritional Status, Post-operative Complications, Length of Stay and Readmission Rates in Patients Undergoing Radical Cystectomy
Status: Enrolling
Updated: 12/10/2014
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Phase I Randomized, Double-blind, Placebo-controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1
Status: Enrolling
Updated:  1/6/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Phase I Randomized, Double-blind, Placebo-controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1
Status: Enrolling
Updated: 1/6/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment
Status: Enrolling
Updated:  1/7/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment
Status: Enrolling
Updated: 1/7/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gastric In Vivo Study
Endoscopic Multispectral Imaging for the Early Detection of Gastric Neoplasia
Status: Enrolling
Updated:  1/12/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Gastric In Vivo Study
Endoscopic Multispectral Imaging for the Early Detection of Gastric Neoplasia
Status: Enrolling
Updated: 1/12/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Status: Enrolling
Updated:  1/15/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Status: Enrolling
Updated: 1/15/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials